Status:
TERMINATED
Memory Phenotype and PD-1 Inhibition Response in Oral Cancer
Lead Sponsor:
Medical University of South Carolina
Conditions:
Squamous Cell Carcinoma of the Head and Neck
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this research study is collect tissue and blood samples from patients who are having surgery and use those samples in lab studies to see if there are any markers in blood and tissue tha...
Detailed Description
Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common neoplasm in the world and despite advances in treatment, the 5-year survival remains approximately 50%. Because of the nee...
Eligibility Criteria
Inclusion
- Newly diagnosed histologically proven locoregional oral squamous cell carcinoma (OSCC) without evidence of distant metastases. OSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone and buccal mucosa OR
- Recurrent or persistent histologically proven locoregional OSCC that was initially treated with surgery alone.
- must be eligible for surgical resection
- greater than 18 years of age
Exclusion
- prior immunotherapy or treatment with another anti PD-1 agent besides nivolumab
- prior chemotherapy including cetuximab or radiation therapy
- concomitant malignancies except cutaneous squamous cell carcinoma or basal cell carcinoma
- unresectable primary tumor or regional disease or distant metastases
Key Trial Info
Start Date :
February 8 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 22 2021
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03862066
Start Date
February 8 2019
End Date
November 22 2021
Last Update
August 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, United States, 29425